Concentric Medical has enrolled first patients in TREVO 2 (Thrombectomy REvascularization of large Vessel Occlusions) at Oregon Health & Science University in Portland, Oregon and at Capital Health in Trenton, New Jersey.
TREVO 2 is a pivotal clinical trial investigating the safety and efficacy of Concentric’s Trevo Retriever for removing clot from ischemic stroke patients.
The Trevo Retriever utilizes Stentriever technology, a novel method for retrieving clot from the neurovasculature and is designed for quick access, rapid clot integration and predictable clot retrieval in ischemic stroke patients.
The TREVO 2 study will build upon Concentric’s previous clot retrieval trials, MERCI and Multi MERCI, which have provided compelling evidence of the benefits of retrieving stroke-causing clots from the blood vessels of acute ischemic stroke patients.